Cargando…

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma

SIMPLE SUMMARY: Multiple Myeloma (MM) is the most common cancer of the bone marrow and remains incurable despite advances in novel therapy. The disease course is typically characterized by an initial response pattern to treatment followed by eventual relapse and treatment refractoriness. Patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yarlagadda, Lakshmi, Gundarlapalli, Sravani, Parikh, Richa, Landes, Reid D., Kottarathara, Mathew, Ogunsesan, Yetunde, Hoque, Shadiqul, Mitma, Angel A., Bailey, Clyde, Hill, Kerri M., Thanendrarajan, Sharmilan, Graziutti, Monica, Mohan, Meera, Zangari, Maurizio, van Rhee, Frits, Tricot, Guido, Schinke, Carolina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392190/ https://www.ncbi.nlm.nih.gov/pubmed/34439174 http://dx.doi.org/10.3390/cancers13164019

Ejemplares similares

Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
por: Larsen, Kristin, et al.
Publicado: (2022)

Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status
por: Baker, David, et al.
Publicado: (2021)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2023)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2022)

Infection Risk Associated with Daratumumab
por: Johnsrud, Joyce J, et al.
Publicado: (2017)

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
por: Al Hadidi, Samer, et al.
Publicado: (2022)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States
por: Al Hadidi, Samer, et al.
Publicado: (2022)

Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma
por: Al Hadidi, Samer, et al.
Publicado: (2023)

Sixth Nerve Palsy From Multiple Myeloma in Central Nervous System: Case Series and Review of Current Literature
por: Thalambedu, Nishanth, et al.
Publicado: (2023)

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
por: Mazahreh, Farah, et al.
Publicado: (2023)

3195 Genomic Analysis of Primary Plasma Cell Leukemia reveals Complex Cytogenetic Alterations and High Risk Mutational Patterns
por: Schinke, Carolina, et al.
Publicado: (2019)

Variability of definition of high‐risk multiple myeloma across phase III clinical trials
por: Abu Za'nouneh, Faris Jamal, et al.
Publicado: (2023)

EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
por: Ling, Wen, et al.
Publicado: (2023)

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
por: Sawyer, Jeffrey R., et al.
Publicado: (2019)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns
por: Schinke, Carolina, et al.
Publicado: (2020)

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
por: Choudhury, Samrat Roy, et al.
Publicado: (2020)

Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant
por: Mathur, Pankaj, et al.
Publicado: (2017)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Gai, Dongzheng, et al.
Publicado: (2022)

Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
por: Schinke, Carolina, et al.
Publicado: (2022)

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
por: Ashby, Cody, et al.
Publicado: (2019)

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
por: Rasche, Leo, et al.
Publicado: (2022)

High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
por: Cheng, Yan, et al.
Publicado: (2023)

Severe Right-Sided Heart Failure and Pulmonary Hypertension with Carfilzomib Treatment in Multiple Myeloma
por: Mathur, Pankaj, et al.
Publicado: (2020)

Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma
por: Mathur, Pankaj, et al.
Publicado: (2017)

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma
por: Davies, Faith E., et al.
Publicado: (2018)

Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?
por: Rasche, Leo, et al.
Publicado: (2019)

Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases
por: Molle, Ingolf, et al.
Publicado: (2022)

282. Epidemiology of Candidemia in Patients with Solid Tumors of the Gastrointestinal Tract
por: Vasylyeva, Olga, et al.
Publicado: (2019)

Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy
por: Kikuchi, Takaki, et al.
Publicado: (2020)

Kinase domain activation through gene rearrangement in multiple myeloma
por: Morgan, Gareth J, et al.
Publicado: (2018)

Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
por: Mikulasova, Aneta, et al.
Publicado: (2022)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Necrotizing Enterocolitis in a Patient With Newly Diagnosed Multiple Myeloma and Hyperviscosity Syndrome: A Case Report
por: Patel, Tanvi H, et al.
Publicado: (2023)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

COVID‐19 and acute pancreatitis: A systematic review
por: Babajide, Oyedotun Ikechukwu, et al.
Publicado: (2022)

P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pasvolsky, Oren, et al.
Publicado: (2023)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n26jq0kf26vac2hi0au44294en